Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View Plans2-year historical trend showing revenue and diluted EPS
Sanofi India's revenue declined 30.4% and EPS declining 31.4% YoY in FY2024, indicating broad-based weakness.
In FY 2024, Sanofi India's revenue declined by 30.4% year-over-year, while EPS declined by 31.4%. Revenue Growth: Shows Sanofi India's top-line expansion over time. Consistent revenue growth indicates market share gains, successful product launches, or pricing power. Look for steady upward trends rather than erratic spikes.
EPS Growth: Earnings Per Share growth measures profitability on a per-share basis. Growing EPS faster than revenue indicates improving profit margins and operational efficiency. The ideal scenario is both metrics growing together at healthy rates.
The Compound Annual Growth Rate shows the mean annual growth rate over specified time periods.
| METRIC | 1-YEAR CAGR | 5-YEAR CAGR | 10-YEAR CAGR |
|---|---|---|---|
|
Revenue
|
-30.4% | Upgrade | Upgrade |
|
Income
|
-31.4% | Upgrade | Upgrade |
|
EPS
|
-31.4% | Upgrade | Upgrade |
• CAGR calculations exclude periods with negative starting values or where values cross from positive to negative
• Green indicates positive growth, red indicates decline
Sanofi India's 10-year revenue CAGR of 0.3% reflects slow growth, with EPS CAGR of 4.6% outpacing revenue, indicating improving profitability.
CAGR smooths out year-to-year volatility to show the steady annual growth rate over a period. 1-year captures recent momentum, 5-year reveals business cycle performance, and 10-year reflects durable competitive advantages.
Revenue CAGR above 15%, and EPS CAGR above 20% are generally considered excellent. Compare across all three periods and with industry peers for context.
Trend showing Sanofi India's revenue alongside key operational metrics
This chart is available with a paid plan. Get deeper insights into company fundamentals with full access to all charts and metrics.
Account Receivables: Money owed to Sanofi India by customers for goods or services delivered. Rising receivables relative to revenue may indicate collection issues or aggressive revenue recognition. Ideally, receivables should grow proportionally with revenue.
Inventories: Value of raw materials, work-in-progress, and finished goods. High inventory levels relative to revenue may suggest slow-moving stock or overproduction. Low inventory with rising revenue indicates efficient inventory management and strong demand.
Year-over-year growth in retained earnings showing Sanofi India's profit accumulation
Sanofi India's retained earnings declined 55.1% YoY in FY2024.
Over 2 years (FY2023–FY2024), retained earnings declined by 55.1%, from 9.92B to 4.46B.
In FY 2024, Sanofi India's retained earnings declined by 55.1% year-over-year. What are Retained Earnings: Retained earnings represent the cumulative net income that Sanofi India has retained, rather than distributed to shareholders as dividends. It reflects Sanofi India's ability to reinvest profits back into the business for growth, debt reduction, or other purposes.
Growth Interpretation: Consistent growth in retained earnings indicates strong profitability and effective capital allocation. Negative growth may signal losses, high dividend payouts, or share buybacks. Compare with revenue and net income growth to assess overall financial health.
Year-over-year growth in dividend per share showing Sanofi India's dividend payout trend
Sanofi India's dividend per share decreased 55.7% YoY in FY2024, having paid dividends in 10 of the last 10 years.
In FY 2024, Sanofi India paid a dividend of Rs. 167.00 per share. What is DPS: Dividend Per Share (DPS) represents the total dividends paid out to shareholders divided by the number of outstanding shares. It indicates how much cash return investors receive for each share they own.
Growth Interpretation: Consistent DPS growth indicates management's confidence in future earnings and commitment to rewarding shareholders. Companies with steady dividend growth are often financially stable and mature. Compare with earnings growth to assess dividend sustainability.
Efficiency metric showing average days to collect payment from customers
This chart is available with a paid plan. Get deeper insights into company fundamentals with full access to all charts and metrics.
What is DSO: Days Sales Outstanding measures the average number of days it takes Sanofi India to collect payment after making a sale. Formula: (Account Receivables / Revenue) × 365. Lower DSO indicates faster cash collection and better working capital management.
Industry Context: DSO varies by industry. B2B companies typically have 30-60 days DSO, while B2C companies often have lower DSO. Compare with industry peers and payment terms offered to customers.
Interpretation: Increasing DSO may indicate collection problems, aggressive revenue recognition, or relaxed credit terms. Decreasing DSO suggests improving collection efficiency or stricter credit policies. Sudden spikes warrant investigation into customer creditworthiness or sales quality.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2024